Stock of the Week <style type="text/css">.ReadMsgBody { width: 100%; background-color: #E6F0FA; } .ExternalClass { width: 100%; background-color: #E6F0FA; } .ExternalClass, .ExternalClass p, .ExternalClass span, .ExternalClass font, .ExternalClass td, .ExternalClass div { line-height: 100%; } body { margin: 0; padding: 0; -webkit-text-size-adjust: none; -ms-text-size-adjust: none; } div, p, a, li, td { -webkit-text-size-adjust: none; -ms-text-size-adjust: none; } table td { -webkit-text-size-adjust: none; border-spacing: 0; border-collapse: collapse; border:0 none; mso-table-lspace: 0pt; mso-table-rspace: 0pt; } a[href^="https"] { text-decoration: none; } /* Constrain email width for small screens */ @media screen and (max-width: 650px) { table[class="container"] { width: 96%!important; -moz-box-sizing:border-box; -webkit-box-sizing:border-box; box-sizing:border-box; margin:0 auto; } } /* Styles for forcing columns to rows */ @media only screen and (max-width : 650px) { /* force container columns to (horizontal) blocks */ td[class="force-col"] { display: block; text-align: left; width: auto!important; } img[class="fullwidth-img"] { width: 100%!important; } /* Make telephone numbers pretty */ a[href~="tel"] { color:#d35400!important; } /* OFFERS TABLE LAYOUT */ td[class="offers-table-header-force-col"] { border-bottom:none!important; display: block; text-align: left; width: auto!important; } td[class="offers-table-force-col"] { display: block; text-align: left; width: auto!important; padding:0 10px 10px!important; } /* TEXT WITH IMAGE LAYOUT */ td[class="textimg-img-col"] { border-bottom:none!important; display: block; text-align: left; width: auto!important; padding:10px 10px 0!important } td[class="textimg-text"] { border-bottom:none!important; display: block; text-align: left; width: auto!important; } /* 3 COL LAYOUTS */ table[class="col-3"] { border-bottom:1px solid #535353; margin-bottom:12px; } table[id="last-col-3"] { border-bottom:none; margin-bottom:0; } img[class="col-3-img"] { float: right; margin-left: 6px; max-width: 130px; } }</style>

Stock of the Week Logo
One Big Pick. Once a Week.


RATED A "STRONG BUY" WITH A TINY FLOAT, NDTP COULD BE THE NEXT OTC PHARMA PLAY TO GO PARABOLIC!


logo
NDT PHARMACEUTICALS INC.

US PINK SYMBOL: NDTP 
Last Price: 1.39  |    Website   |    SEC Filings   |    Latest News


Before you fire up those turkey's for Thanksgiving...fire up those trading screens because we're headed back to the Penny Markets with a unique Pharma play that's starting to pick up steam!

With a super LOW FLOAT, this penny play started lighting up screens due to a recent acquisition in the Wellness space.

This puts Today's Alert in the midst of a $6.8 TRILLION global wellness industry market, projected to grow to $7.4 trillion in 2025 and an anticipated rise to $9.8 trillion by 2029!

Need we say more?

WE ARE ISSUING AN IMMEDIATE ALERT ON NDTP FOR THIS WEEK!

NDT Pharmaceuticals, Inc. (OTC: NDTP) is a publicly traded company focused on advancing innovative consumer health and wellness solutions.

With its recent acquisition of Good Salt Life Inc., NDTP has expanded its strategic direction into sustainable, science-driven products that promote healthier living. The Company is committed to building value through investments in brands that protect people, pets, and the planet while aligning with growing consumer demand for eco-friendly and health-conscious alternatives.

So what's the hype on NDTP's Good Salt Life Inc?

Good Salt Life Inc. is a unique biosafety and sanitation tech company using HOCl (hypochlorous acid) — a compound used in hospitals, emergency medicine, and high-grade cleaning environments.

good salt

But here’s the key:

🔥 NDTP's GOOD SALT LIFE™ is NOT just selling “cleaning products.”

They are developing EPA-registered, hospital-tested, medical-grade biosafety systems — AND selling consumer versions via huge retail channels.

This includes: Amazon, Walmart, Chewy, Retail & hospitality partners, Cruise lines, Hospitals, Clinics, Senior living centers, Luxury hotels, and Pet-care facilities.

And the crown jewel:

👉 Their ByoCart™ Disinfection System has already been deployed in healthcare environments — including Baptist Hospital.

cruise

Not to mention, NDTP is EXPANDING their offering with NORWEGIAN CRUISE LINES!

This is SERIOUS validation.
This is REAL deployment.
This is an ACTUAL operational subsidiary — NOT a “concept.
 

Here’s what NDTP is rolling out:

🧪 HOCl antimicrobial technology — clinically backed, non-toxic
🚼 Baby-safe & pet-safe cleaning line
🚢 Cruise & hospitality biosafety systems
🏥 Hospital-grade air purification & surface systems
🐶 Pet wellness sanitization products
🏬 Retail-ready SKU lineup for large chains
🧰 ByoCart™ mobile disinfection system


On October 9th, the company submitted a "me-too" registration application to the U.S. Environmental Protection Agency (EPA) for its hypochlorous acid (HOCl) disinfectant, which, if approved, would expand the label to include an efficacy claim for Clostridioides difficile (C. diff) on its label.

"We are extremely excited about this important milestone and are eagerly awaiting the EPA's decision, and if approval is granted, it will represent a major milestone," said Bill Spilfogel, Senior Vice President of Regulatory Affairs and spokesperson for Good Salt Life.

"Approval of a C. diff efficacy claim would represent a groundbreaking advancement for Good Salt Life, solidifying our mission to enhance biosecurity in critical environments."


Needless to say, NDTP is NOT just another OTC biotech claiming the world.  NDTP has a real operating subsidiary with distribution already underway.

chart


Here’s what the chart is telling us:

📈 Price hovering above long-term trendlines
📈 Resistance thinning → small volume can break levels
📈 MACD curling underneath — potential bullish cross?
📈 RSI sitting in neutral territory = room to run
📈 Support forming under recent price action
📈 Tightening = pre-breakout coil

We’ve seen this pattern countless times:

When low-float OTC stocks coil quietly… the move is rarely quiet.

And with NDTP’s recent chart Breakout & TINY Float of just 16.9 MIL shares a/o 8/16/2025, ANY continuation of this momentum could create a MAJOR MOVE.


strong buy

Not to mention, Investing.com has now given NDTP it's highest rating of "STRONG BUY"


THE BOTTOM LINE
For an OTC Penny Stock in the Pharma/Wellness Sector, NDTP absolutely checks every box...

🔥 A GROWING operating subsidiary (Good Salt Life™)
🔥 Targeting a massive global market
🔥 Distribution in big-box retail ecosystems
🔥 HOCl tech = trending in both medical and consumer health
🔥 Low float
🔥 OTC = explosive potential on volume surges

If retailers add more SKUs…
If Good Salt expands its commercial rollouts…
If a new hospital validates ByoCart…
If Amazon sales spike…

NDTP is EXACTLY the kind of low-float speculative play that can explode with the right catalyst at the right time.

AND WALL STREET IS BARELY WATCHING NDTP… YET!

No analysts.
No glowing research notes.
No mainstream fund ownership.
No CNBC segments.

Barely a soul is watching this.  But this is EXACTLY how major low-float runs start.

REMEMBER WHERE YOU HEARD OF NDTP FIRST!

Make sure you put it on your screen TOMORROW MORNING  and Follow on Twitter  for Updates + Play-by-Play!

Good Trading,

Editor
StockoftheWeek.net


sms       telegram


Still need an Online Broker to place trades?
Etrade  

Do NOT use RobinHood! Our Team HIGHLY recommends ETRADE .
 


Website   |   Unsubscribe   |   View in Browser

Disclaimer1
We encourage all to read the SEC's INVESTOR ALERT before reading this Newsletter.

COMPENSATION:   Stockoftheweek.net has been compensated fifty-five thousand dollars cash via bank wire by a third party, Shore Thing Media, LLC for this NDT Pharmaceuticals, Inc. marketing services contract. Stockoftheweek.net does not own any shares of NDTP.  Stockoftheweek.net does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.

Disclaimer2